ALK Reports Strong Financial Results for Q2 2024
According to Company release No. 16/2024, ALK achieved an impressive 21% organic revenue growth alongside an operating profit margin of 19% in Q2 (unaudited). This significant revenue increase was primarily driven by robust tablet sales, along with enhanced performance in injection- and drop-based allergy immunotherapy products. The European and International markets played a vital role in this growth. Furthermore, ALK's operating profit (EBIT) surged by 189%, aligning with the company's financial objectives and leading to an upgraded outlook for the full year.
Q2 Performance Highlights
When comparing results to Q2 2023, ALK showcased remarkable achievements. The revenue growth rates, expressed in local currencies, are as follows:
- Total revenue rose by 21% in local currencies, reaching DKK 1,374 million, up from DKK 1,135, indicating widespread growth.
- Tablet sales experienced a 32% increase, totaling DKK 716 million, compared to DKK 547, with double-digit growth observed across all sales regions. Europe was a significant contributor, achieving 35% growth.
- Combined sales of SCIT and SLIT-drops grew by 16%, reaching DKK 490 million from DKK 423, bolstered by strong growth in Europe and increased SCIT shipments to China.
- Sales from Other products and services grew slightly by 1%, totaling DKK 168 million, up from DKK 165. Jext sales rose by 17% as it recovers from prior supply shortages, while other products experienced a decline.
Overview of Financial Highlights
Operating profit (EBIT) saw substantial growth, climbing by 189% in local currencies to DKK 264 million from DKK 97, achieving an EBIT margin of 19%, up from 9% the previous year. This progress can be attributed to various factors, including sales growth, improved gross margins, and effective cost management strategies that have successfully reduced overall costs across R&D, Sales & Marketing, and Administration. It’s worth noting that the EBIT figures included one-off costs of DKK 38 million related to optimization initiatives.
Strategic Developments and Future Outlook
ALK is dedicated to implementing its new strategy, ‘Allergy+’, which was launched on June 3, 2024, and sets ambitious long-term financial goals for 2028. The strategy's execution has begun, focusing on high-potential growth opportunities.
- Regulatory processes are actively underway to secure approvals for house dust mite and tree pollen allergy tablets for children in both European and North American markets, with launch preparations on track for 2024/25. Additionally, a clinical trial for the peanut allergy tablet is expected to report its next set of results in the latter half of 2024.
- After withdrawing the house dust mite allergy tablet license application for China, ALK is collaborating with local authorities to meet the documentation requirements needed for local approval.
- Optimization efforts are progressing well to reallocate resources for growth investments, aligning with the 2025 earnings goal of achieving a 25% EBIT margin.
Revised Full-Year Financial Outlook
In reference to Company Announcement No. 15/2024 released earlier, the full-year financial outlook has been revised upwards. Revenue is now expected to grow by 14-16% organically in local currencies, an increase from the previous estimate of 12-15%, largely due to widespread growth across various sales regions and product categories. European tablet sales continue to be a crucial driver of this growth.
- The EBIT margin is projected to improve to 19-21%, revised from an earlier estimate of 18-20%, compared to last year’s margin of 14%. This enhancement is primarily driven by accelerated sales growth, accounting for approximately DKK 60 million in one-off costs related to optimization efforts.
CEO’s Insights on Q2 Results
In his comments on the Q2 results, CEO Peter Halling remarked: "The results in 2024 have exceeded our expectations thus far, and we are particularly pleased with the ongoing strong growth in tablet sales and the positive effects of our cost optimization initiatives. The rollout of our new strategy ‘Allergy+’ is progressing well, and we have begun taking significant steps to effectively scale ALK for future revenue and earnings growth.”
Frequently Asked Questions
What were the key revenue growth figures for ALK in Q2 2024?
ALK reported a 21% increase in total revenue for Q2 2024, reaching DKK 1,374 million.
How did ALK's EBIT perform in Q2 2024?
The EBIT for Q2 2024 increased by 189%, amounting to DKK 264 million, with an EBIT margin of 19%.
What strategic initiatives are driving ALK's growth?
ALK's growth is being driven by its new strategy ‘Allergy+’, which focuses on high-potential growth levers and optimizing operational efficiencies.
What is the full-year outlook for ALK's financial performance?
The full-year outlook has been upgraded to reflect a projected revenue growth of 14-16% organically, and an EBIT margin of 19-21%.
Who can be contacted for more information regarding ALK?
For further information, interested parties can contact Per Plotnikof in Investor Relations at +45 4574 7527 or Maiken Riise Andersen in Media at +45 5054 1434.
